Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 16.9% in February

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the recipient of a large decline in short interest during the month of February. As of February 27th, there was short interest totaling 82,219 shares, a decline of 16.9% from the February 12th total of 98,894 shares. Based on an average daily trading volume, of 25,376 shares, the short-interest ratio is presently 3.2 days. Approximately 1.2% of the shares of the company are short sold. Approximately 1.2% of the shares of the company are short sold. Based on an average daily trading volume, of 25,376 shares, the short-interest ratio is presently 3.2 days.

Lixte Biotechnology Trading Down 2.0%

LIXT stock traded down $0.06 during midday trading on Tuesday, hitting $3.01. The company’s stock had a trading volume of 50,040 shares, compared to its average volume of 28,988. The firm’s 50-day moving average is $3.16 and its 200-day moving average is $4.02. Lixte Biotechnology has a 12 month low of $0.64 and a 12 month high of $6.26. The company has a market cap of $22.51 million, a PE ratio of -2.55 and a beta of 0.86.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lixte Biotechnology in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Investors Weigh In On Lixte Biotechnology

Several institutional investors have recently modified their holdings of LIXT. Axxcess Wealth Management LLC purchased a new position in Lixte Biotechnology in the 4th quarter worth about $54,000. Geode Capital Management LLC boosted its holdings in shares of Lixte Biotechnology by 25.9% during the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock valued at $205,000 after acquiring an additional 10,722 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Lixte Biotechnology by 47.0% during the 4th quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock valued at $422,000 after acquiring an additional 34,350 shares during the last quarter. DRW Securities LLC grew its stake in shares of Lixte Biotechnology by 11.6% in the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock worth $213,000 after acquiring an additional 5,645 shares during the period. Finally, Federation des caisses Desjardins du Quebec grew its stake in shares of Lixte Biotechnology by 83.6% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock worth $367,000 after acquiring an additional 42,530 shares during the period. 5.10% of the stock is owned by hedge funds and other institutional investors.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.